Interferon lambda inhibits dengue virus replication in epithelial cells.
Helen K. Palma-Ocampo,Helen K. Palma-Ocampo,Juan Carlos Flores-Alonso,Verónica Vallejo-Ruiz,Julio Reyes-Leyva,Lilian Flores-Mendoza,Irma Herrera-Camacho,Nora Hilda Rosas-Murrieta,Gerardo Santos-López +8 more
TL;DR: Evidence described here suggests that IFN-λ is a good candidate inhibitor of viral replication in dengue infection.
read more
Abstract: In viral disease, infection is controlled at the cellular level by type I interferon (IFN-I), but dengue virus (DENV) has the ability to inhibit this response. Type III interferon, also known as lambda IFN (IFN-III or IFN-λ), is a complementary pathway to the antiviral response by IFN-I. This work analyzed the IFN-λ (IFN-III) mediated antiviral response against DENV serotype 2 (DENV-2) infection. Dengue fever patients were sampled to determine their IFN-λ levels by ELISA. To study the IFN-λ response during DENV infection we selected the epithelial cell line C33-A, and we demonstrated that it is permissive to DENV-2 infection. The effect of IFN-λ on virus replication was determined in these cells, in parallel to the expression of IFN-stimulated genes (ISGs), and Suppressor of Cytokine Signaling (SOCS), genes measured by RT-qPCR. We found increased (~1.8 times) serological IFN-λ in dengue fever patients compared to healthy blood donors. IFN-λ inhibited DENV-2 replication in a dose-dependent manner in vitro. The reduction of viral titer corresponded with increased ISG mRNA levels (MX1 and OAS1), with the highest inhibition occurring at ISG’s peak expression. Presence of IFN-negative regulators, SOCS1 and SOCS3, during DENV-2 infection was associated with reduced IFN-λ1 expression. Evidence described here suggests that IFN-λ is a good candidate inhibitor of viral replication in dengue infection. Mechanisms for the cellular and organismal interplay between DENV and IFN- λ need to be further studied as they could provide insights into strategies to treat this disease. Furthermore, we report a novel epithelial model to study dengue infection in vitro.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
The continued threat of emerging flaviviruses
TL;DR: The basic biology of these viruses, their life cycles, the diseases they cause and available therapeutic options are reviewed, and the global distribution of flaviviruses is discussed, with a focus on lesser-known species that have the potential to emerge more broadly in human populations.
Biochemistry and Molecular Biology of Flaviviruses
Nicholas J. Barrows,Nicholas J. Barrows,Rafael K. Campos,Rafael K. Campos,Kuo-Chieh Liao,K. Reddisiva Prasanth,Ruben Soto-Acosta,Shih Chia Yeh,Geraldine Schott-Lerner,Julien Pompon,Julien Pompon,October M. Sessions,Shelton S. Bradrick,Mariano A. Garcia-Blanco,Mariano A. Garcia-Blanco +14 more
TL;DR: This review examines the molecular biology of flaviviruses touching on the structure and function of viral components and how these interact with host factors, and highlights the role of a noncoding RNA produced by flavIViruses to impair antiviral host immune responses.
280
Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection.
Kazumoto Murata,Mai Asano,Akihiro Matsumoto,Masaya Sugiyama,Nao Nishida,Eiji Tanaka,Taisuke Inoue,Minoru Sakamoto,Nobuyuki Enomoto,Takayoshi Shirasaki,Masao Honda,Shuichi Kaneko,Hiroyuki Gatanaga,Shinichi Oka,Yuki I. Kawamura,Taeko Dohi,Yasutaka Shuno,Hideaki Yano,Masashi Mizokami +18 more
TL;DR: It is discovered that the nucleotide analogues show an additional pharmacological effect by inducing IFN-λ3 production, which further induces ISGs and results in a reduction of HBsAg production.
171
Cellular and Molecular Pathways of COVID-19 and Potential Points of Therapeutic Intervention
TL;DR: A coherent cellular and molecular pathway is proposed for COVID-19, consistent with a broad range of observed clinical features and biological markers and captures key mediators of pathophysiology.
Interferon Lambda: Modulating Immunity in Infectious Diseases.
TL;DR: This review summarizes the emerging details of the IFN-λ immunobiology in the context of the host immune response and viral and bacterial infections and describes and associated with the clinical course and treatment outcomes of hepatitis B and C virus infection.
References
The global distribution and burden of dengue
Samir Bhatt,Peter W. Gething,Oliver J. Brady,Jane P. Messina,Andrew Farlow,Catherine L. Moyes,John M. Drake,John M. Drake,John S. Brownstein,Anne G. Hoen,Osman Sankoh,Osman Sankoh,Monica F. Myers,Dylan B. George,Thomas Jaenisch,G. R. William Wint,Cameron P. Simmons,Thomas W. Scott,Thomas W. Scott,Jeremy Farrar,Jeremy Farrar,Simon I. Hay,Simon I. Hay +22 more
TL;DR: These new risk maps and infection estimates provide novel insights into the global, regional and national public health burden imposed by dengue and will help to guide improvements in disease control strategies using vaccine, drug and vector control methods, and in their economic evaluation.
Dengue: a continuing global threat
María G. Guzmán,Scott B. Halstead,Harvey Artsob,Philippe Buchy,Jeremy Farrar,Duane J. Gubler,Elizabeth Hunsperger,Axel Kroeger,Harold S. Margolis,Eric Martinez,Michael B. Nathan,José L. Pelegrino,Cameron P. Simmons,Sutee Yoksan,Rosanna W. Peeling,Rosanna W. Peeling +15 more
TL;DR: A global strategy aimed at increasing the capacity for surveillance and outbreak response, changing behaviours and reducing the disease burden using integrated vector management in conjunction with early and accurate diagnosis has been advocated.
2.1K
IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex.
Sergei V. Kotenko,Grant Gallagher,Vitaliy V. Baurin,Anita Lewis-Antes,Meiling Shen,Nital K. Shah,Jerome A. Langer,Faruk Sheikh,Harold Dickensheets,Raymond P. Donnelly +9 more
TL;DR: The identification of a ligand-receptor system that, upon engagement, leads to the establishment of an antiviral state and may contribute to antiviral or other defenses by a mechanism similar to, but independent of, type I IFNs.
1.8K
IL-28, IL-29 and their class II cytokine receptor IL-28R.
Paul O. Sheppard,Wayne R. Kindsvogel,Wenfeng Xu,Katherine E. Henderson,Stacy Schlutsmeyer,Theodore E. Whitmore,Rolf E. Kuestner,Ursula Garrigues,Carl W. Birks,Jenny Roraback,Craig D. Ostrander,Dennis L. Dong,Jinu Shin,Scott R. Presnell,Brian A. Fox,Betty A. Haldeman,Emily Cooper,David W. Taft,Teresa Gilbert,Francis J. Grant,Tackett Monica L,William Krivan,Gary L. McKnight,Chris Clegg,Don Foster,Kevin M. Klucher +25 more
TL;DR: A family of three cytokines, designated interleukin 28A, IL-28B and IL-29, that are distantly related to type I interferons (IFNs) and the IL-10 family are identified and may serve as an alternative totype I IFNs in providing immunity to viral infection.
1.7K
Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures.
TL;DR: Applied aspects that arise from an increase in knowledge in this area are described, including vaccine design and manufacture, the development of novel antiviral drugs and the use of IFN-sensitive oncolytic viruses in the treatment of cancer.
1.6K
Related Papers (5)
[...]
Samir Bhatt,Peter W. Gething,Oliver J. Brady,Jane P. Messina,Andrew Farlow,Catherine L. Moyes,John M. Drake,John M. Drake,John S. Brownstein,Anne G. Hoen,Osman Sankoh,Osman Sankoh,Monica F. Myers,Dylan B. George,Thomas Jaenisch,G. R. William Wint,Cameron P. Simmons,Thomas W. Scott,Thomas W. Scott,Jeremy Farrar,Jeremy Farrar,Simon I. Hay,Simon I. Hay +22 more